CNBX Pharmaceuticals Granted Patent in Hong Kong

TEL AVIV, Israel and BETHESDA, Md., May 5, 2022 

CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, today announced that it has received a Grant of Patent notice by the Patent Registry, Intellectual Property Department, The Government of the Hong Kong Special Administrative Region. Said notice relates to the Company’s patent titled: System and Method for High Throughput Screening of Cancer Cells.

The Company further reported that it believes that the granting of this patent by the Hong Kong Patent Registry validates its innovative approach to drug discovery in using data obtained from high throughput screening (HTS) of compounds on various types of cancer cells to elucidate and identify specific compounds that are most effective as anti-cancer agents.

This process has already been instrumental for the Company in producing several promising cancer treatment drug candidates, which are now at various stages of the regulatory pathway, including its novel drug candidate RCC-33 for the treatment of colorectal cancer.

About CNBX Pharmaceuticals:

CNBX Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit For the latest updates on CNBX Pharmaceuticals, follow the Company on Twitter @cnbxpharma, Facebook @cnbxPharmaceuticals, LinkedIn, and Instagram @CNBX_Pharmaceuticals.


Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed April 12, 2022. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about CNBX Pharmaceuticals Inc. approved by the Company come from the Company itself and bear our name as its source.